Clinical effectiveness of ethinylestradiol-cyproterone acetate and raloxifene combination therapy in polycystic ovary syndrome-associated infertility

The document highlights the significant health and economic burdens of Polycystic Ovary Syndrome (PCOS), stressing the importance of early diagnosis and intervention to reduce risks of comorbidities and healthcare costs. Women with PCOS are at increased risk for cardiovascular events, endometrial cancer, gestational diabetes, hypertensive disorders during pregnancy, and metabolic-associated fatty liver disease. The syndrome is linked to insulin resistance and obesity, and it has a genetic basis with familial factors and specific genetic loci contributing to its development. PCOS is also associated with psychological distress, mental health disorders, and an elevated risk of various cancers. Comprehensive management guidelines are needed to address these challenges and improve diagnosis and treatment strategies.